Teza Capital Management’s Pacira BioSciences PCRX Stock Holding History

Teza Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,098	Closed	-$276K	–	445
2025 Q1	$276K	Sell	11,098 -2,319	-17%	-$55.5K	0.13%	277
2024 Q4	$253K	Sell	13,417 -2,172	-14%	-$38.1K	0.04%	391
2024 Q3	$235K	Buy	15,589 +2,375	+18%	+$40.6K	0.03%	522
2024 Q2	$378K	Sell	13,214 -5,741	-30%	-$163K	0.05%	407
2024 Q1	$554K	Buy	18,955 +10,596	+127%	+$326K	0.07%	326
2023 Q4	$282K	Sell	8,359 -2,140	-20%	-$62.6K	0.05%	426
2023 Q3	$322K	Buy	10,499 +858	+9%	+$30.9K	0.05%	416
2023 Q2	$386K	Buy	+9,641	New	+$399K	0.06%	341
2020 Q3	–	Sell	-8,027	Closed	-$421K	–	547
2020 Q2	$421K	Buy	+8,027	New	+$335K	0.09%	324
2018 Q4	–	Sell	-6,563	Closed	-$323K	–	447
2018 Q3	$323K	Buy	+6,563	New	+$284K	0.07%	309

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Teza Capital Management's PCRX Position: Q2 2025 in Review

Teza Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 11,098 shares — an estimated $276K sold.

Teza Capital Management first reported a position in PCRX in Q3 2018 and held it in 10 quarters. The position peaked at $554K in Q1 2024. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

Teza Capital Management reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
Teza Capital Management sold 11,098 Pacira BioSciences shares in Q2 2025, an estimated $276K.
Teza Capital Management first reported a position in Pacira BioSciences in Q3 2018 and held it in 10 quarters.
Teza Capital Management's Pacira BioSciences position peaked at $554K in Q1 2024.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.